Loading...

Tonix Pharmaceuticals Holding

DB:TPMP
Snowflake Description

Excellent balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
TPMP
DB
$14M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering and developing pharmaceutical products to treat serious neuropsychiatric conditions and to improve biodefense. The last earnings update was 37 days ago. More info.


Add to Portfolio Compare Print
  • Tonix Pharmaceuticals Holding has significant price volatility in the past 3 months.
TPMP Share Price and Events
7 Day Returns
-3.8%
DB:TPMP
-0.1%
DE Biotechs
1%
DE Market
1 Year Returns
-91.8%
DB:TPMP
-7.4%
DE Biotechs
-5.6%
DE Market
TPMP Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Tonix Pharmaceuticals Holding (TPMP) -3.8% -3.3% 21.9% -91.8% -99.2% -99.7%
DE Biotechs -0.1% 6% -6.7% -7.4% 53.2% 11.6%
DE Market 1% 6.1% 8.4% -5.6% 10.9% 13.8%
1 Year Return vs Industry and Market
  • TPMP underperformed the Biotechs industry which returned -7.4% over the past year.
  • TPMP underperformed the Market in Germany which returned -5.6% over the past year.
Price Volatility
TPMP
Industry
5yr Volatility vs Market
Related Companies

TPMP Value

 Is Tonix Pharmaceuticals Holding undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Tonix Pharmaceuticals Holding. This is due to cash flow or dividend data being unavailable. The share price is €2.012.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Tonix Pharmaceuticals Holding's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Tonix Pharmaceuticals Holding's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:TPMP PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-26.81
NasdaqGM:TNXP Share Price ** NasdaqGM (2019-04-24) in USD $2.22
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.73x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.72x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Tonix Pharmaceuticals Holding.

DB:TPMP PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:TNXP Share Price ÷ EPS (both in USD)

= 2.22 ÷ -26.81

-0.08x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Tonix Pharmaceuticals Holding is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Tonix Pharmaceuticals Holding is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Tonix Pharmaceuticals Holding's expected growth come at a high price?
Raw Data
DB:TPMP PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.08x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts
15.7%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 269 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Tonix Pharmaceuticals Holding, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Tonix Pharmaceuticals Holding's assets?
Raw Data
DB:TPMP PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $7.28
NasdaqGM:TNXP Share Price * NasdaqGM (2019-04-24) in USD $2.22
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.72x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.87x
DB:TPMP PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:TNXP Share Price ÷ Book Value per Share (both in USD)

= 2.22 ÷ 7.28

0.31x

* Primary Listing of Tonix Pharmaceuticals Holding.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Tonix Pharmaceuticals Holding is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Tonix Pharmaceuticals Holding's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Tonix Pharmaceuticals Holding has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

TPMP Future Performance

 How is Tonix Pharmaceuticals Holding expected to perform in the next 1 to 3 years based on estimates from 5 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
15.7%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Tonix Pharmaceuticals Holding expected to grow at an attractive rate?
  • Unable to compare Tonix Pharmaceuticals Holding's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Tonix Pharmaceuticals Holding's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • Unable to compare Tonix Pharmaceuticals Holding's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:TPMP Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:TPMP Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts 15.7%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.6%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:TPMP Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:TPMP Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 32 -3 1
2022-12-31 13 -19 2
2021-12-31 12 -28 3
2020-12-31 0 -27 4
2019-12-31 0 -27 5
DB:TPMP Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 -24 -29
2018-09-30 -22 -24
2018-06-30 -22 -24
2018-03-31 -21 -23
2017-12-31 -19 -21
2017-09-30 -20 -23
2017-06-30 -23 -25
2017-03-31 -27 -30
2016-12-31 -37 -39
2016-09-30 -44 -45
2016-06-30 -48 -50
2016-03-31 -49 -52

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Tonix Pharmaceuticals Holding is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Unable to determine if Tonix Pharmaceuticals Holding is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:TPMP Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below

All data from Tonix Pharmaceuticals Holding Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:TPMP Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 -0.90 -0.90 -0.90 1.00
2022-12-31 -2.28 -2.25 -2.30 2.00
2021-12-31 -0.89 1.40 -2.45 3.00
2020-12-31 -5.69 -2.37 -10.70 3.00
2019-12-31 -4.24 -3.97 -4.60 3.00
DB:TPMP Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -26.81
2018-09-30 -28.52
2018-06-30 -30.79
2018-03-31 -30.13
2017-12-31 -31.69
2017-09-30 -41.15
2017-06-30 -56.75
2017-03-31 -98.26
2016-12-31 -154.07
2016-09-30 -213.82
2016-06-30 -265.43
2016-03-31 -289.51

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Tonix Pharmaceuticals Holding will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Tonix Pharmaceuticals Holding's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Tonix Pharmaceuticals Holding has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

TPMP Past Performance

  How has Tonix Pharmaceuticals Holding performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Tonix Pharmaceuticals Holding's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Tonix Pharmaceuticals Holding does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Tonix Pharmaceuticals Holding's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Tonix Pharmaceuticals Holding's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Tonix Pharmaceuticals Holding's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Tonix Pharmaceuticals Holding Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:TPMP Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 -29.36 8.76 17.56
2018-09-30 -23.99 8.08 16.34
2018-06-30 -24.30 7.73 16.98
2018-03-31 -22.99 7.67 15.72
2017-12-31 -21.12 7.95 13.34
2017-09-30 -23.11 8.67 14.59
2017-06-30 -24.90 8.89 15.45
2017-03-31 -29.93 9.19 20.86
2016-12-31 -38.84 10.44 28.53
2016-09-30 -44.72 11.72 33.14
2016-06-30 -50.39 12.54 38.69
2016-03-31 -52.35 13.13 39.35
2015-12-31 -48.05 12.66 35.50
2015-09-30 -43.68 11.98 31.79
2015-06-30 -37.85 11.23 26.69
2015-03-31 -32.13 10.29 21.90
2014-12-31 -27.62 9.04 18.62
2014-09-30 -22.33 8.19 14.17
2014-06-30 -18.01 7.43 10.59
2014-03-31 -14.05 6.60 7.46
2013-12-31 -10.88 6.24 4.65
2013-09-30 -9.81 5.07 4.02
2013-06-30 -8.45 4.69 3.04
2013-03-31 -9.44 4.58 2.93
2012-12-31 -9.45 4.08 2.58
2012-09-30 -8.41 3.83 2.41
2012-06-30 -7.69 3.28 2.24

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Tonix Pharmaceuticals Holding has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Tonix Pharmaceuticals Holding has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Tonix Pharmaceuticals Holding improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Tonix Pharmaceuticals Holding's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Tonix Pharmaceuticals Holding has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

TPMP Health

 How is Tonix Pharmaceuticals Holding's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Tonix Pharmaceuticals Holding's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Tonix Pharmaceuticals Holding is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Tonix Pharmaceuticals Holding has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Tonix Pharmaceuticals Holding's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Tonix Pharmaceuticals Holding has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Tonix Pharmaceuticals Holding Company Filings, last reported 3 months ago.

DB:TPMP Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 23.66 0.00 25.03
2018-09-30 13.71 0.00 14.67
2018-06-30 15.84 0.00 16.68
2018-03-31 18.61 0.00 19.25
2017-12-31 24.62 0.00 25.50
2017-09-30 28.68 0.00 29.31
2017-06-30 33.97 0.00 34.36
2017-03-31 21.98 0.00 22.42
2016-12-31 25.36 0.00 26.12
2016-09-30 27.11 0.00 26.74
2016-06-30 30.03 0.00 31.25
2016-03-31 27.34 0.00 27.49
2015-12-31 40.26 0.00 43.02
2015-09-30 52.65 0.00 55.05
2015-06-30 46.24 0.00 48.74
2015-03-31 56.89 0.00 58.18
2014-12-31 36.09 0.00 38.18
2014-09-30 43.78 0.00 46.23
2014-06-30 42.66 0.28 43.87
2014-03-31 47.92 0.28 49.55
2013-12-31 6.51 0.28 8.20
2013-09-30 5.44 0.28 7.42
2013-06-30 -1.96 0.20 0.07
2013-03-31 -0.64 0.00 0.42
2012-12-31 0.96 0.00 1.79
2012-09-30 -0.67 0.00 0.04
2012-06-30 0.71 0.00 1.34
  • Tonix Pharmaceuticals Holding has no debt.
  • Tonix Pharmaceuticals Holding has no debt compared to 5 years ago when it was 4%.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Tonix Pharmaceuticals Holding has less than a year of cash runway based on current free cash flow.
  • Tonix Pharmaceuticals Holding has sufficient cash runway for 1.1 years if free cash flow continues to reduce at historical rates of -33.2% each year.
X
Financial health checks
We assess Tonix Pharmaceuticals Holding's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Tonix Pharmaceuticals Holding has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

TPMP Dividends

 What is Tonix Pharmaceuticals Holding's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Tonix Pharmaceuticals Holding dividends.
If you bought €2,000 of Tonix Pharmaceuticals Holding shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Tonix Pharmaceuticals Holding's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Tonix Pharmaceuticals Holding's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:TPMP Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:TPMP Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Tonix Pharmaceuticals Holding has not reported any payouts.
  • Unable to verify if Tonix Pharmaceuticals Holding's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Tonix Pharmaceuticals Holding's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Tonix Pharmaceuticals Holding has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Tonix Pharmaceuticals Holding's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Tonix Pharmaceuticals Holding afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Tonix Pharmaceuticals Holding has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

TPMP Management

 What is the CEO of Tonix Pharmaceuticals Holding's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Seth Lederman
COMPENSATION $1,477,445
AGE 60
TENURE AS CEO 7.5 years
CEO Bio

Dr. Seth Lederman, M.D., is a Co-Founder of Tonix Pharmaceuticals Holding Corp. (formerly, Krele Pharmaceuticals) and has been its Chairman, Chief Executive Officer, President and Director since October 7, 2011. Dr. Lederman founded Tonix Pharmaceuticals, Inc., in June of 2007 and has acted as its Chairman of the Board of Directors since its inception and as President since June 2010. Dr. Lederman is an inventor on key patents and patent applications underlying programs including: TNX-102 SL’s eutectic composition; Tonmya’s pharmacokinetic profile and related therapeutic properties, and Tonmya for posttraumatic stress disorder (PTSD). Dr. Lederman was a Co-Founder of IVREA Pharmaceuticals, Inc. He is a physician, scientist and specialty pharmaceuticals entrepreneur. Dr. Lederman was the Scientific Founder of Targent, LLC. In 2000, he founded Targent Pharmaceuticals to develop late-stage oncology drugs including pure-isomer levofolinic acid, which was sold to Spectrum Pharmaceuticals and is FDA-approved and marketed as Fusilev® for colorectal cancer. Between January 2007 and November 2008, Dr. Lederman was a Co-Founder and Managing Partner of Konanda Pharma Partners. He was a Co-Founder and Managing Partner of Konanda Pharma Partners, LLC and Konanda Pharma Partners Fund I, L.P./Konanda Pharma Fund I, LP. As well, between January 2007 and November 2008, Dr. Lederman co-founded and served as director and chairman of its wholly-owned operating companies Validus and Fontus Pharmaceuticals Inc., which market Equetro® (carbamazepine – Extended Release), Marplan® (isocarboxazid) and Rocaltrol® (calcitriol). He was a Founder or Co-Founder of a number of specialty pharmaceuticals companies. He has devised cell-based screens and used them to identify new drugs, new targets and new signaling pathways. Dr. Lederman co-founded Vela Pharmaceuticals Inc. in 1998. Dr. Lederman served as Associate Professor at Columbia University until April 13, 2017. He joined the faculty of Columbia University's College of Physicians and Surgeons in 1985, became Assistant Professor of Medicine in 1988 and Associate Professor with tenure in 1996 and Director of the Laboratory of Molecular Immunology in 1997. Dr. Lederman has been a Manager of L&L Technologies LLC, or L&L, since 1996. In addition, Dr. Lederman has been the Managing Member of Seth Lederman Co, LLC since January 2007 and the Managing Member of Lederman & Co, LLC, or Lederman & Co, since 2002. Dr. Lederman serves as a Director of Metastatin Pharmaceuticals, Inc. He served as a Director of Targent, LLC. Since December 2011, Dr. Lederman has served as CEO and Chairman of Leder Laboratories Inc., or Leder Labs, and Starling Pharmaceuticals Inc., or Starling, which are biopharmaceutical development companies. Since March 2013, Dr. Lederman has been the chairman of Leder Laboratories, Ltd., a wholly-owned subsidiary of Leder Laboratories Inc. In 2015, Dr. Lederman served as a member of the US – Japan Business Council. Between 2006 and 2011, Dr. Lederman was a director of Research Corporation, a New York-based non-profit organization. From 1988 to 2002, he directed basic science research at Columbia in molecular immunology, infectious diseases and the development of therapeutics for autoimmune diseases. His fundamental work on the CD40-Ligand (CD154) elucidated the molecular basis of T cell helper function and has led to the development of therapeutic candidates for autoimmune diseases and organ transplant rejection in collaboration with Biogen-IDEC and CellTech/UCB. The successful defense of his CD154 patents has led to important precedents in defining the relationship of therapeutics and molecular targets. In collaboration with Prof. David Baltimore (then at Rockefeller University and later MIT), Dr. Lederman identified and functionally characterized the CD40 signaling molecule, TRAF-3. His early work on HIV contributed to the understanding of how the V3 loop of HIV gp120 was involved in fusion with CD4 cell membranes, an early and essential event in viral entry and infection. In addition to his research, he served as attending physician in the Edward Daniels Arthritis and Autoimmunity Clinic on the Medical Service at Columbia Presbyterian Hospital from 1988 to 1996. Dr. Lederman was a NIH Physician-Scientist (from 1985 to 1990) at Columbia. He is author of numerous scientific articles and inventor of technologies recognized by a number of issued patents. He trained in internal medicine and rheumatology at Columbia's Presbyterian Hospital and obtained MD from Columbia University's College of Physicians and Surgeons in 1983. Dr. Lederman graduated from Columbia Medical School in Medicine. Dr. Lederman earned an A.B. in Chemistry at Princeton University with Honors in 1979.

CEO Compensation
  • Seth's compensation has increased whilst company is loss making.
  • Seth's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Tonix Pharmaceuticals Holding management team in years:

3.2
Average Tenure
56
Average Age
  • The tenure for the Tonix Pharmaceuticals Holding management team is about average.
Management Team

Seth Lederman

TITLE
Co-Founder
COMPENSATION
$1M
AGE
60
TENURE
7.5 yrs

Bradley Saenger

TITLE
CFO & Treasurer
COMPENSATION
$616K
AGE
44
TENURE
3.2 yrs

Greg Sullivan

TITLE
Chief Medical Officer & Secretary
COMPENSATION
$722K
AGE
52
TENURE
4.8 yrs

Jessica Morris

TITLE
Chief Operating Officer
COMPENSATION
$418K
TENURE
3.2 yrs

Ron Notvest

TITLE
Executive Vice President of Commercial Planning and Development
TENURE
3.2 yrs

Daniel Clauw

TITLE
Consultant

R. Gendreau

TITLE
Consultant
AGE
62
Board of Directors Tenure

Average tenure and age of the Tonix Pharmaceuticals Holding board of directors in years:

7.5
Average Tenure
62.5
Average Age
  • The tenure for the Tonix Pharmaceuticals Holding board of directors is about average.
Board of Directors

Seth Lederman

TITLE
Co-Founder
COMPENSATION
$1M
AGE
60
TENURE
7.5 yrs

Patrick Grace

TITLE
Director
COMPENSATION
$66K
AGE
62
TENURE
7.5 yrs

John Rhodes

TITLE
Lead Director
COMPENSATION
$99K
AGE
88
TENURE
5.2 yrs

Margaret Bell

TITLE
Director
COMPENSATION
$66K
AGE
58
TENURE
1.6 yrs

Donald Landry

TITLE
Co-Founder & Director
COMPENSATION
$66K
AGE
63
TENURE
7.5 yrs

Daniel Goodman

TITLE
Member of Scientific Advisory Board

Iredell Iglehart

TITLE
Member of Scientific Advisory Board

Herbert Harris

TITLE
Member of Scientific Advisory Board

Harvey Moldofsky

TITLE
Member of Scientific Advisory Board
TENURE
7.8 yrs

David Grange

TITLE
Director
COMPENSATION
$84K
AGE
70
TENURE
1.2 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Tonix Pharmaceuticals Holding insiders in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
01. Apr 19 Buy Seth Lederman Individual 29. Mar 19 29. Mar 19 5,000 €2.22 €11,084
28. Mar 19 Buy Seth Lederman Individual 26. Mar 19 26. Mar 19 25,000 €2.10 €52,600
02. Jul 18 Buy Seth Lederman Individual 29. Jun 18 29. Jun 18 50 €39.77 €1,988
29. Jun 18 Buy Seth Lederman Individual 28. Jun 18 28. Jun 18 50 €39.52 €1,976
28. Jun 18 Buy Seth Lederman Individual 27. Jun 18 27. Jun 18 50 €39.25 €1,962
27. Jun 18 Buy Ernest Mario Individual 25. Jun 18 25. Jun 18 1,650 €38.30 €63,202
15. Jun 18 Buy Gregory Sullivan Individual 14. Jun 18 14. Jun 18 1,000 €34.04 €34,040
14. Jun 18 Buy Lederman & Co, LLC Company 12. Jun 18 12. Jun 18 200 €37.07 €7,414
14. Jun 18 Buy Seth Lederman Individual 12. Jun 18 12. Jun 18 100 €37.07 €3,707
14. Jun 18 Buy Bradley Saenger Individual 14. Jun 18 14. Jun 18 30 €35.20 €1,056
14. Jun 18 Buy Jessica Morris Individual 14. Jun 18 14. Jun 18 30 €35.97 €1,079
06. Jun 18 Buy John Rhodes Individual 01. Jun 18 01. Jun 18 750 €28.53 €21,399
30. May 18 Buy Seth Lederman Individual 25. May 18 25. May 18 400 €27.20 €10,878
X
Management checks
We assess Tonix Pharmaceuticals Holding's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Tonix Pharmaceuticals Holding has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

TPMP News

Simply Wall St News

TPMP Company Info

Description

Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering and developing pharmaceutical products to treat serious neuropsychiatric conditions and to improve biodefense. Its lead product candidate is TNX-102 SL or Tonmya that is designed as a bedtime administration for posttraumatic stress disorder (PTSD), which is in Phase 3 study in the military-related PTSD population. The company is also developing TNX-601 (tianeptine oxalate), a pre-investigational new drug (pre-IND) application stage, designed as a daytime administration for the treatment of PTSD; and TNX-801, a live synthetic version of horsepox virus at the pre-IND application stage. Its product pipeline also includes TNX-301, a potential treatment for AUD; and TNX-701, a biodefense development program for protection from radiation injury. Tonix Pharmaceuticals Holding Corp. was founded in 2007 and is based in New York, New York.

Details
Name: Tonix Pharmaceuticals Holding Corp.
TPMP
Exchange: DB
Founded: 2007
$12,079,402
6,089,728
Website: http://www.tonixpharma.com
Address: Tonix Pharmaceuticals Holding Corp.
509 Madison Avenue,
Suite 306,
New York,
New York, 10022,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM TNXP Common Stock Nasdaq Global Market US USD 10. Oct 2011
DB TPMP Common Stock Deutsche Boerse AG DE EUR 10. Oct 2011
Number of employees
Current staff
Staff numbers
12
Tonix Pharmaceuticals Holding employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/24 22:31
End of day share price update: 2019/04/24 00:00
Last estimates confirmation: 2019/04/23
Last earnings filing: 2019/03/18
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.